Mikayel Mkrtichyan

This inventor holds 18 USPTO granted patents and 21 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignees: Augusta University Research Institute, Inc., Pds Biotechnology Corporation, The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2017-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mikayel Mkrtichyan. Retrieved from https://idiyas.com/inventor/mikayel-mkrtichyan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18 (Patent Applications = 21)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 15)

EPO Patents = 3 (Patent Applications = 19)

Average Co-Inventor Count = 2.5

ph-index = 5

Forward Citations = 48(Granted Patents)

Location History:

Augusta, GA (US) (2017)
Rockville, MD (US) (2019 - 2020)
Millbrae, CA (US) (2018 - 2022)
Tujunga, CA (US) (2021 - 2024)

Company Filing History:

14 out of 72

Augusta University Research Institute, Inc.

patents

3 out of 14

Pds Biotechnology Corporation

patents

3 out of 3,693

The United States of America, as Represented by the Secretary, Department of Health and Human Services

where one patent can have more than one assignee

Years Active: 2017-2026

Loading Chart...

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12616690 - SPECIFIC AKT3 ACTIVATOR AND USES THEREOF (2026-05-05),

2. 12209127 - Antibodies to programmed cell death protein 1 (2025-01-28),

3. 12201685 - Methods of modulating immune responses with cationic lipid vaccine compositions (2025-01-21),

4. 12168687 - Antibodies to programmed cell death protein 1 that are PD-1 agonists (2024-12-17),

5. 11957673 - Specific AKT3 activator and uses thereof (2024-04-16),

6. 11780921 - Antibodies to programmed cell death protein 1 (2023-10-10),

7. 11291719 - Methods and compositions for modulating Akt3 (2022-04-05),

8. 11021540 - Antibodies to programmed cell death protein 1 (2021-06-01),

9. 11013735 - Specific Akt3 inhibitor and uses thereof (2021-05-25),

10. 10980878 - Methods and compositions for modulating Akt3 activity (2021-04-20),

11. 10828364 - Method for reducing a myeloid derived suppressor cell population with cationic lipid vaccine compositions (2020-11-10),

12. 10588966 - Methods and compositions for inhibiting Akt3 (2020-03-17),

13. 10525049 - Specific Akt3 inhibitor and uses thereof (2020-01-07),

14. 10342868 - Methods and compositions for inhibiting Akt3 (2019-07-09),

15. 10292978 - Specific Akt3 inhibitor and uses thereof (2019-05-21),

Title: The Groundbreaking Innovations of Mikayel Mkrtichyan

Introduction: Mikayel Mkrtichyan, a prolific inventor based in Millbrae, California, has made significant contributions to the field of biomedical research with a remarkable portfolio of 17 patents. His work primarily focuses on enhancing immune responses, which is crucial in the development of therapies for various diseases.

Latest Patents: Among his latest innovations are antibodies targeting programmed cell death protein 1 (PD-1). These antibodies and their antigen-binding fragments uniquely bind to PD-1, challenging the conventional belief that PD-1 solely promotes immune suppression. Instead, Mkrtichyan's inventions are designed to activate immune cells, thereby promoting proliferation and enhancing cytokine production. Additionally, he has developed cationic lipid vaccine compositions that comprise therapeutic factors and adjuvants. These compositions are aimed at reducing immune suppressor cell populations and augmenting immune responses in mammals, showcasing his dedication to advancing immunotherapy.

Career Highlights: Throughout his career, Mkrtichyan has worked with reputable organizations including the Augusta University Research Institute and PDS Biotechnology Corporation. His roles within these institutions have enabled him to apply his inventive acumen to real-world biomedical challenges.

Collaborations: Mikayel has collaborated with notable colleagues such as Samir N. Khleif and Iryna Lebedyeva. These partnerships have fostered an environment of shared knowledge and innovation, further propelling advancements in the field of immunology.

Conclusion: Mikayel Mkrtichyan's innovative contributions to immunotherapy and vaccine development are paving the way for more effective treatments in the medical field. His 17 patents reflect a deep commitment to understanding and manipulating immune responses, which holds the promise of transforming patient outcomes in various diseases. With ongoing research and collaboration, his work continues to inspire innovation in biomedical science.

Profile summary based on public USPTO records.